Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Fiskars Group investing in Digital & IT capabilities

Fiskars CorporationPress releaseAugust 19, 2021 at 10:00 EEST  Fiskars Group investing in Digital & IT capabilities Fiskars Group is focusing on creating organic growth in the longer term. A strong digital business is a pre-requisite for growth and while the company has invested in this field, it is committed to doing more.The company’s clear digital ambition entails building strong capabilities within data, direct to consumer and consumer experience online. “Data is increasingly important for Fiskars Group as it plays an essential role in everything, and we need to be

EOS Russia - Half year report 1 January - 30 June 2021

· The loss for EOS during the period was SEK -21.7 million (-174.6). Loss per share was SEK -0.63 (-4.75). Total comprehensive income for the period was SEK 3.8 million (-165.6). · EOS recorded a net loss from investing activities of SEK -15.9 million (-167.9) comprising net dividends of SEK 19.9 million and a negative development in the investment portfolio of SEK -35.8 million. · Operating expenses amounted to SEK -5.8 million (-6.4).  · Net financial items for the period amounted to SEK -0.0 million (-0.4).  · EOS’ net asset value at June 30, 2021 was SEK 647 million (739).

Interim Report Second Quarter 2021

NASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER: STENOSTENOCARE A/S (“STENOCARE”) today announces its results for the period 01.01.2021 – 30.06.2021. The report is attached to this release and is also available on https://stenocare.com/investor-relations/ Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments: “Q2 brought clarity to the future of the medical cannabis industry in Denmark. The Danish Pilot Programme for treatment of patients was extended with another four-years, and cultivation/production is permanently legal. This is very good news for both patients and for the

Cantargia publishes half year report

Cantargia AB’s (”Cantargia”) half year report for the period January until June 2021 is now available on the company’s web page www.cantargia.com/en/investors/financial-reports.Significant events in the second quarter · Preclinical results for the CAN10 antibody were presented at the IMMUNOLOGY2021 conference. · A letter of intent was signed with GEICAM to conduct a clinical study with nadunolimab in combination with carboplatin/gemcitabine in triple negative breast cancer. · Positive interim results were presented from the CANFOUR study showing an improved progression-free

ExpreS2ion announces financial results for the second quarter of 2021

Hørsholm, Denmark, August 19, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its second quarter financial results for 2021. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.CEO Bent U. Frandsen comments “During the second quarter of 2021, we reported on continued progress in key pipeline areas for ExpreS[2]ion including COVID-19, breast cancer and malaria, while also securing 39 MSEK in additional funding from the exercise of warrants of series TO4. I want to start this CEO comment with

MEDIVIR AB – INTERIM REPORT JANUARY – JUNE 2021

Positive study results for MIV-818 and remetinostat. Design determined for the combination study with MIV-818April – JuneFinancial summary for the quarter · Net turnover amounted to SEK 0.9 (4.0) million. · The loss before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -17.1 (-12.4) million. Basic and diluted earnings per share amounted to SEK -0.35 (-0.52) and SEK -0.35 (-0.52) respectively. · Cash flow from operating activities amounted to SEK -21.9 (-23.3) million. · Liquid assets and short-term investments at the end of the period amounted to SEK

Scandion Oncology A/S announces its results for the first half year of 2021

Scandion Oncology today announces its half year report for 2021. The following is taken from the report. Bo Rode Hansen, President and CEO comments “Positive interim CORIST results highlight an intensive quarter - The second quarter of 2021 was as busy and rewarding as the first three months. We reached several milestones both clinically and organizationally. Most importantly, we reported positive interim results from our Phase IIclinical study CORIST.” Key figures & highlights TDKK Q2 2021 Q2 2020 Q1-Q2 2021 Q1-Q2 2020 2020 Net sales

Interim report Jan-June 2021

Clinics build experienceSecond Quarter 2021 · Revenue amounted to SEK 411 (6,263) thousand, of which SEK 383 (5,787) thousand were capitalized costs. · Loss after tax amounted to SEK-18,263 (-5,516) thousand. · Loss per share SEK -0.30 (-0.18). · Cash and cash equivalents amounted to SEK 48,339 (7,177) thousand. First half of 2021 · Revenues amounted to SEK 816 (12,531) thousand, of which SEK 762 (12,090) thousand capitalized costs. · Cash flow from operating activities amounted to SEK -23,999 (-13,107) thousand. · Profit after tax amounted to SEK -35,519 (-12,

Completion of accelerated bookbuilt offering of existing shares in HusCompagniet A/S

Company announcement 15/2021 NOT FOR DISTRIBUTION IN THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA. THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.  THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY, NOR SHALL THERE BE ANY SALE OF THE SECURITIES REFERRED TO HEREIN, IN OR INTO ANY JURISDICTION WHERE SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL PRIOR TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES

Interim report 2021 Everysport Media Group AB (publ)

Acquisition of Every Padel, high sales growth and record-high result"I am very pleased with the development of Everysport Media Group (ESMG) during the second quarter. We report higher net sales than ever, SEK 58.1 million (SEK 17.8 million), a record high result, and the group has made important acquisitions at the same time as major strategic steps have been taken" says Hannes Andersson, CEO ESMGSummary of the second quarter 2021 · Net sales*: 58,1 mkr (17,8 mkr) · EBITDA: 16,4 mkr (−0,8 mkr) · EBIT: 7,5 mkr (−1,7 mkr) · Profit after tax: 4,1 mkr (−2,2 mkr) · Earnings

Adverty partners with Azerion to further strengthen in-game advertising’s programmatic reach

The partnership with Azerion's premium advertising platform (Improve Digital), designed to enable more advertisers to leverage its market-leading programmatic in-game offering. The partnership and integration are planned for an October 2021 launch.Adverty, the leading in-game platform for advertisers, agencies and game developers, has announced a partnership with Azerion's premium advertising platform (Improve Digital), which will increase its programmatic reach for brands and advertisers looking to enter the increasingly influential world of gaming. Adverty delivers unobtrusive

Fazer Aito Oat Drink has a small carbon footprint – Calculating the carbon footprint is a part of the company’s ambitious climate work

As part of its ambitious sustainability approach and actions to mitigate climate change, Fazer conducted a carbon footprint study on Fazer Aito Oat Drink in collaboration with an external expert. The carbon footprint is 0.23 kg CO\2\e/kg, which is a small footprint for a food product. Fazer’s goal is to cut emissions by 50% by 2030.One litre of Fazer Aito Oat Drink, including the product packaging, has a carbon footprint of 0.23 kg CO\2\e/kg. The amount is equivalent to the emissions caused by using a filter coffee machine for three hours. The study produced a theoretical calculation of how

Asarina Pharma AB (publ) Q2 Report 2021 released

Asarina Pharma CEO Peter Nordkild: “Q2 2021 was a difficult quarter for us and our shareholders. It was also a definitively transformative one. The failure of our Phase IIa study in Menstrual Migraine coincided with the approval of our CTA in Tourette syndrome by the Danish Medicines Agency, and the granting of our first US patent for Sepranolone for the treatment of Tourette, OCD and pathological gambling. Together, these developments signal the end of an important chapter in our history, and the beginning of a new journey.”FINANCIAL HIGHLIGHTS · Operating costs (SEK 16.0 million)

MPC Container Ships Invest B.V. reports Q2 and six-month 2021 results

Oslo/Rhoon, 19 August 2021 - MPC Container Ships Invest B.V. (the "Company", together with its subsidiaries the "Group") today published its unaudited financial report for the six-month period ended 30 June 2021. The Group reported a net profit of USD 5.3 million for Q2 2021 (Q1 2021: net loss of USD 1.0 million). As at 30 June 2021, the Group owns 37 container vessels between 1,000 – 2,800 TEU. Further information and contact: ir@mpc-container.com About MPC Container Ships Invest B.V.: The Company was formed in September 2017 as a wholly-owned subsidiary of MPC Container

Metso Outotec provides cutting edge flotation technology for nickel concentrator in Australia

Metso Outotec Corporation’s press release on August 19, 2021, at 09:00 a.m. EESTMetso Outotec will supply cutting edge flotation technology for a major nickel producer in Western Australia as part of their concentrator modernization. The site is one of the largest nickel producing sites in the world. Start-up of the new flotation cells is scheduled for 2022. The order value, which is not disclosed, has been booked in Minerals’ Q3/2021 orders received. Metso Outotec’s delivery includes nickel rougher and cleaner flotation technology based on new and proprietary Concorde Cell™ flotation

High Volume division makes acquisition in China

Mycronic’s Assembly Solutions High Volume division has signed an agreement to acquire Shenzhen Huan Cheng Xin Precision Manufacture Co., Ltd., a company with around 120 employees and headquarters in Shenzhen, China. Shenzhen Huan Cheng Xin Precision Manufacture Co., Ltd. produces automated screen printers and pick & place machines. Screen printers account for 80 percent of sales and pick & place machines for the remaining 20 percent. China is the company’s dominating market, accounting for 95 percent of sales. ”With this acquisition we strengthen and broaden High Volume’s product

Modus Therapeutics publishes interim report for the second quarter 2021

STOCKHOLM, SWEDEN - 19 august 2021: Modus Therapeutics Holding AB (”Modus Therapeutics”) hereby publishes an interim report for the second quarter 2021. The interim report is available as an attached document and on the company's website (www.modustx.com). Below is a summary of the interim report.The second quarter in figures · The loss after tax amounted to TSEK 2,533 (1,698). · Cash flow from operating activities amounted to TSEK -2,299 (-2,267) · Cash and cash equivalents amounted to TSEK 3,830 (4,395) The first half-year in figures · The loss after tax amounted to

Second quarter report Q2-2021 - planning for the pivotal trials

Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1 April – 30 June 2021. The second quarter report is available as an attached document to this press release and on www.cessatech.com under Investor, ‘Filings & Reports’. The company is on track with planned activities, has completed recruitment for the bioavailability trial 0204 and is ready to initiate recruitment of trial 0206 - a trial to investigate the pharmacokinetics in children aged 1-17 undergoing elective surgical procedures.Second quarter 2021 (1 April – 30 June): · Net revenue was KDKK 0

TC TECH Sweden AB (publ) publishes its interim report

TC TECH has today published its interim report for the period January 1 to June 30, 2021.Net sales amounted to 0 (0) TSEK in the second quarter of 2021. In the same period, net profit/loss totalled -2 557 (-5 249) TSEK. Cash flow from operating activities was  -1 716 (-2 986) TSEK in the period from April 1[st] to June 30[th] 2021. Net sales amounted to 0 (105) TSEK in the first half of 2021, while net profit/loss totalled -6 657 (-12 657) TSEK. Cash flow from operating activities was -5 519 (-10 328) TSEK in the period from 1 January to 30 June 2021.

InDex Pharmaceuticals conducts PK study with cobitolimod

August 19, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced that the company will conduct a clinical pharmacokinetic study (PK study) with cobitolimod in Sweden. The Swedish Medical Products Agency has given approval to start the study.The purpose of the study is to evaluate the systemic uptake of cobitolimod in local treatment of colonic inflammation. The study will include at least 6 patients with moderate to severe ulcerative colitis treated with doses of 500 mg of cobitolimod administered rectally. First the uptake of cobitolimod will be measured in patients with active

Fortum and Valmet Automotive co-operate in sustainable recycling of battery materials

FORTUM CORPORATION BUSINESS PRESS RELEASE 19.8.2021  Fortum and Valmet Automotive, one of the leading producers of battery systems and largest vehicle contract manufacturers, have entered into a cooperation to ensure the safe and sustainable recycling of all non-conforming battery materials from Valmet Automotive’s battery plants in Salo and Uusikaupunki.  “We are proud to collaborate with Valmet Automotive, a leading player in the battery systems manufacturing industry,” says Tero Holländer, Head of Business Line, Batteries, Fortum. “Our collaboration will enable us to recover raw

Sivers Semiconductors AB (publ), Interim Report Q2, January – June 2021

Second quarter 2021 · Revenue amounted to SEK 26.911 M (21.445), an increase of 25% · Profit before depreciation and amortization (EBITDA) amounted to SEK -20.080 M (-9.068) · Operating profit/loss (EBIT) for the period was SEK -28.009 M (-16.590) · Profit/loss after tax was SEK -28.897 M (-22.392) · Earnings per share before and after dilution was SEK -0.19 (-0.16) · Equity per share amounted to SEK 3.13 (2.15)January-June 2021 · Revenue amounted to SEK 40.751 M (44.255), a decrease of 8% · Profit before depreciation and amortization (EBITDA) amounted to SEK -37.

Interim report

January 1 – June 30, 2021The second quarter in figures · Net sales amounted to TSEK 2,258 (1,683). · The loss after tax amounted to TSEK 11,151 (8,864). · The loss per share amounted to SEK 0.19 (0.38). · The cash flow from current operations was negative in the amount of TSEK 9,162 (8,704). · The gross margin reached 56.3% (55.7%). · Electrode sales volume increased by 28% and reached 5,968 (4,672) units. Repeat sales of electrodes to existing customers increased by 23%. January - June in figures · Net sales amounted to TSEK 4,821 (4,179). · The loss after

Q2 Report 2021 – invitation to conference call and audiocast

Stockholm, August 19, 2021 - On Thursday, August 26, at 09.00 CET, IRRAS will host a conference call and an online presentation of its Q2 2021 interim report (which will have been published earlier on August 26 at 08.00 CET). The presentation will be held in English. The dial-in numbers for the conference call are: Sweden: +46 8 50 55 83 54Rest of the world: +44 33 33 00 92 73 The presentation will be webcast and can be accessed from the following web address:https://tv.streamfabriken.com/irras-q2-2021 Speakers: President and CEO Will Martin, Interim CFO Griffen Stapp, and

There are no items matching the current filter
There are no more items matching the current filter
Back to top